BRIEF-Abeona gets orphan drug status for genetic skin disorder treatment

* Abeona Therapeutics receives FDA orphan drug designation for EB-101 gene therapy product for patients with epidermolysis bullosa Source text for Eikon: Further company coverage:

by reutersCOMPANYNEWS via Endless Supplies .Biz - News